| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by operating activities | 123,357 | 83,698 |
| Proceeds from disposal of assets | 435 | 435 |
| Maturities of investments | - | 194,084 |
| Purchases of property and equipment | 9,812 | 8,108 |
| Purchases of available-for-sale securities | 350,078 | 251,705 |
| Maturities of available-for-sale securities | 289,875 | - |
| Net cash (used in) investing activities | -69,580 | -65,294 |
| Proceeds from exercise of stock options | 6,972 | 3,258 |
| Taxes paid related to settlement of restricted stock awards-Restricted Stock Units RSU | 12,121 | 12,116 |
| Taxes paid related to settlement of restricted stock awards-Restricted Stock | 1,812 | 1,812 |
| Net cash (used in) provided by financing activities | -6,961 | -10,670 |
| Effect of exchange rate changes on cash and cash equivalents | 923 | 1,230 |
| Net increase in cash and cash equivalents | 47,739 | 8,964 |
| Cash and cash equivalents at beginning of period | 344,865 | - |
| Cash and cash equivalents at end of period | 392,604 | - |
Krystal Biotech, Inc. (KRYS)
Krystal Biotech, Inc. (KRYS)